Physician profile
Tabitha Chu
NPI 1720629561
$1,051.00
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $457 · 2022: $390 · 2023: $165 · 2024: $38.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $204.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $155.89 | 2021-2022 | |
| Amgen INC. | $105.49 | 2021-2024 | Otezla, Repatha |
| Lilly USA, LLC | $94.61 | 2021-2022 | |
| Abbvie INC. | $89.47 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $71.47 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $64.97 | 2021-2023 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $51.08 | 2021 | |
| Astellas Pharma US INC | $45.68 | 2021-2023 | Myrbetriq |
| Biogen, INC. | $42.11 | 2021 | |
| Indivior INC. | $41.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.46 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.39 | 2022 | |
| Almatica Pharma LLC | $27.23 | 2022 | |
| Daiichi Sankyo INC. | $24.61 | 2024 | Injectafer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.24 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.90 | 2021 | |
| Grifols USA, LLC | $18.48 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.92 | 2023 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.71 | 2021 | |
| Dexcom, INC. | $16.51 | 2022 | |
| Amarin Pharma, INC. | $15.55 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.26 | 2022 | |
| Amneal Pharmaceuticals LLC | $14.75 | 2022 | |
| Alkermes, INC. | $14.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.